Companies
Quantinuum
jointly validated a Generative Quantum AI (GenQAI) framework for pharmaceutical R&D with NVIDIA and Pfizer in 2026, with researchers developing ADAPT-GQE to accelerate quantum-circuit creation for complex molecular models.
- Country
- United Kingdom
EU
Coverage
| EU | US | |
|---|---|---|
| digital-it | ✓ | ✓ |
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | Raised $1.7 billion in gross proceeds from IPO; $1.37 billion raised over 10 rounds total. | stocktitan.net |
| Headcount | Approximately 800 employees. | sec.gov |
| Revenue | $8 million for Q2 2026; $28–$32 million expected for full-year 2026. | qz.com · eqs-news.com · sec.gov · stocktitan.net |
| Headquarters | Broomfield, Colorado. | sec.gov |
| Production site | Signed agreement with a leading global electronics manufacturer for co-development of manufacturing capabilities. medium confidence | eqs-news.com · stocktitan.net |
Independent sources: eqs-news.com · qz.com · sec.gov · stocktitan.net
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Quantum computing for molecular modeling | digital-it | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.